These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 15506921)

  • 1. Zebularine: a new drug for epigenetic therapy.
    Yoo CB; Cheng JC; Jones PA
    Biochem Soc Trans; 2004 Dec; 32(Pt 6):910-2. PubMed ID: 15506921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zebularine: a candidate for epigenetic cancer therapy.
    Bradbury J
    Drug Discov Today; 2004 Nov; 9(21):906-7. PubMed ID: 15501719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of DNA methylation and reactivation of silenced genes by zebularine.
    Cheng JC; Matsen CB; Gonzales FA; Ye W; Greer S; Marquez VE; Jones PA; Selker EU
    J Natl Cancer Inst; 2003 Mar; 95(5):399-409. PubMed ID: 12618505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuous zebularine treatment effectively sustains demethylation in human bladder cancer cells.
    Cheng JC; Weisenberger DJ; Gonzales FA; Liang G; Xu GL; Hu YG; Marquez VE; Jones PA
    Mol Cell Biol; 2004 Feb; 24(3):1270-8. PubMed ID: 14729971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zebularine inhibits human acute myeloid leukemia cell growth in vitro in association with p15INK4B demethylation and reexpression.
    Scott SA; Lakshimikuttysamma A; Sheridan DP; Sanche SE; Geyer CR; DeCoteau JF
    Exp Hematol; 2007 Feb; 35(2):263-73. PubMed ID: 17258075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preferential response of cancer cells to zebularine.
    Cheng JC; Yoo CB; Weisenberger DJ; Chuang J; Wozniak C; Liang G; Marquez VE; Greer S; Orntoft TF; Thykjaer T; Jones PA
    Cancer Cell; 2004 Aug; 6(2):151-8. PubMed ID: 15324698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An epigenetic mechanism for high, synergistic expression of indoleamine 2,3-dioxygenase 1 (IDO1) by combined treatment with zebularine and IFN-γ: potential therapeutic use in autoimmune diseases.
    Xue ZT; Sjögren HO; Salford LG; Widegren B
    Mol Immunol; 2012 Jun; 51(2):101-11. PubMed ID: 22424783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measuring topology of low-intensity DNA methylation sites for high-throughput assessment of epigenetic drug-induced effects in cancer cells.
    Gertych A; Farkas DL; Tajbakhsh J
    Exp Cell Res; 2010 Nov; 316(19):3150-60. PubMed ID: 20813111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Scientists probe shutting down cancer cells by awakening silenced genes.
    Hampton T
    JAMA; 2004 May; 291(19):2301-5. PubMed ID: 15150188
    [No Abstract]   [Full Text] [Related]  

  • 10. Epigenetic inhibitor zebularine activates ear pinna wound closure in the mouse.
    Sass P; Sosnowski P; Podolak-Popinigis J; Górnikiewicz B; Kamińska J; Deptuła M; Nowicka E; Wardowska A; Ruczyński J; Rekowski P; Rogujski P; Filipowicz N; Mieczkowska A; Peszyńska-Sularz G; Janus Ł; Skowron P; Czupryn A; Mucha P; Piotrowski A; Rodziewicz-Motowidło S; Pikuła M; Sachadyn P
    EBioMedicine; 2019 Aug; 46():317-329. PubMed ID: 31303499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical advances in hypomethylating agents targeting epigenetic pathways.
    Cang S; Lu Q; Ma Y; Liu D
    Curr Cancer Drug Targets; 2010 Aug; 10(5):539-45. PubMed ID: 20384584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA methyltransferase inhibitors for cancer therapy.
    Brueckner B; Kuck D; Lyko F
    Cancer J; 2007; 13(1):17-22. PubMed ID: 17464242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA methylation and cancer.
    Kulis M; Esteller M
    Adv Genet; 2010; 70():27-56. PubMed ID: 20920744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin 6 supports the maintenance of p53 tumor suppressor gene promoter methylation.
    Hodge DR; Peng B; Cherry JC; Hurt EM; Fox SD; Kelley JA; Munroe DJ; Farrar WL
    Cancer Res; 2005 Jun; 65(11):4673-82. PubMed ID: 15930285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term epigenetic therapy with oral zebularine has minimal side effects and prevents intestinal tumors in mice.
    Yoo CB; Chuang JC; Byun HM; Egger G; Yang AS; Dubeau L; Long T; Laird PW; Marquez VE; Jones PA
    Cancer Prev Res (Phila); 2008 Sep; 1(4):233-40. PubMed ID: 19138966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug reactivates genes to inhibit cancer.
    Foubister V
    Drug Discov Today; 2003 May; 8(10):430-1. PubMed ID: 12801788
    [No Abstract]   [Full Text] [Related]  

  • 17. Zebularine: a unique molecule for an epigenetically based strategy in cancer chemotherapy.
    Marquez VE; Kelley JA; Agbaria R; Ben-Kasus T; Cheng JC; Yoo CB; Jones PA
    Ann N Y Acad Sci; 2005 Nov; 1058():246-54. PubMed ID: 16394141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zebularine-induced myeloma cell death is accompanied by decreased c-Myc expression.
    Krzeminski P; García-Sanz R; Gutiérrez NC
    Cell Oncol (Dordr); 2020 Aug; 43(4):743-750. PubMed ID: 32394351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decitabine, a new star in epigenetic therapy: the clinical application and biological mechanism in solid tumors.
    Nie J; Liu L; Li X; Han W
    Cancer Lett; 2014 Nov; 354(1):12-20. PubMed ID: 25130173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetic regulation of protein tyrosine phosphatases: potential molecular targets for cancer therapy.
    Jacob ST; Motiwala T
    Cancer Gene Ther; 2005 Aug; 12(8):665-72. PubMed ID: 15803146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.